



APR 16 2002

CERTIFICATE OF MAILING																			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.																			
Typed or Printed Name	Donna Macedo																		
Signature			Date May 14, 2002																
INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e)		<table border="1"><tr><td>Attorney Docket</td><td>STAN-201</td></tr><tr><td>First Named Inventor</td><td>CRABTREE, GERALD R.</td></tr><tr><td>Application Number</td><td>09/960,708</td></tr><tr><td>Confirmation No.</td><td>4284</td></tr><tr><td>Filing Date</td><td>September 19, 2001</td></tr><tr><td>Group Art Unit</td><td>1635</td></tr><tr><td>Examiner Name</td><td>Unassigned</td></tr><tr><td colspan="2">Title: "METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS"</td></tr></table>		Attorney Docket	STAN-201	First Named Inventor	CRABTREE, GERALD R.	Application Number	09/960,708	Confirmation No.	4284	Filing Date	September 19, 2001	Group Art Unit	1635	Examiner Name	Unassigned	Title: "METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS"	
Attorney Docket	STAN-201																		
First Named Inventor	CRABTREE, GERALD R.																		
Application Number	09/960,708																		
Confirmation No.	4284																		
Filing Date	September 19, 2001																		
Group Art Unit	1635																		
Examiner Name	Unassigned																		
Title: "METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS"																			
Address to: Assistant Commissioner for Patents Washington, D.C. 20231																			

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.


No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. STAN-201.

**COPY OF PAPERS
ORIGINALLY FILED**

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 5/14/02

By:


Bret E. Field, Reg. No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

**COPY OF PAPERS
ORIGINALLY FILED**

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				<p align="center">Complete If Known</p> <table border="1"> <tr> <td>Application Number</td> <td>09/960,708</td> </tr> <tr> <td>Filing Date</td> <td>September 19, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>CRABTREE, GERALD R.</td> </tr> <tr> <td>Group Art Unit</td> <td>1635</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>STAN-201</td> </tr> </table>		Application Number	09/960,708	Filing Date	September 19, 2001	First Named Inventor	CRABTREE, GERALD R.	Group Art Unit	1635	Examiner Name	Unassigned	Attorney Docket Number	STAN-201
Application Number	09/960,708																
Filing Date	September 19, 2001																
First Named Inventor	CRABTREE, GERALD R.																
Group Art Unit	1635																
Examiner Name	Unassigned																
Attorney Docket Number	STAN-201																
Sheet	1	of	1	<p align="right">RECEIVED</p> <p align="right">JUN 11 2002 TECH CENTER 1000/290</p>													

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		6,096,515		Crabtree et al.	08-01-2000	

FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No. ¹	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
		HERNANDEZ et al. "Selective Inhibition of Vascular Endothelial Growth Factor-mediated Angiogenesis by Cyclosporin A; Roles of the Nuclear Factor of Activated T Cells and Cyclooxygenase 2" <i>J. Exp Med.</i> , Vol. 193, No. 5, March 5, 2001 pp 607-620				

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.